MASH Drug Landscape 2026: $8B Mega-Deals & FGF21 Pipeline
The 2025 MASH/MASLD landscape: GSK, Roche, Novo Nordisk mega-deals, FGF21 analog pipelines, and competitive realignment maps for pharma professionals.
Introduction
MASH (Metabolic Dysfunction-Associated Steatohepatitis) has emerged as an area of intense pharmaceutical industry focus due to extremely high unmet medical needs. The year 2025 has been transformative, with major Big Pharma acquisitions significantly reshaping the competitive landscape.
This article provides a comprehensive analysis of the MASH development race in 2025 from the perspectives of acquisitions, partnerships, and approvals.
Quick Answer: 2025 was a consolidation year in MASH: three Big Pharma mega-deals totaling over $8B reshaped the field — GSK→Boston Pharma ($1.2B), Roche→89bio (up to $3.5B), and Novo Nordisk→Akero ($5.2B). The acquisitions centered on FGF21 analogs (efimosfermin, pegozafermin, efruxifermin), while Rezdiffra's approval and Wegovy's MASH expansion defined the emerging market.
[!TIP] Cross-disease market view To place this MASH M&A wave (GSK / Roche / Novo Nordisk, $8B+ combined) within the broader fibrosis drug market — including IPF and CKD market sizes, deals, and pipeline opportunities — see Fibrosis Drug Market 2026: IPF, MASH, CKD Forecasts.
[!TIP] F4 cirrhosis as the strategic axis ENLIGHTEN-Cirrhosis (pegozafermin F4), the Akero deal milestone tied to compensated cirrhosis approval, and MAESTRO-NASH-OUTCOMES (resmetirom F4) all hinge on the compensated/decompensated cirrhosis boundary and decompensation-prevention endpoints. The clinical definitions (HVPG, MELD 3.0, Child-Pugh, Baveno VII, AASLD 2024) and trial-design implications are detailed in Compensated vs Decompensated Cirrhosis: MASH Endpoint Guide.
MASH: Wave of Big Pharma Mega-Acquisitions
Major Acquisition Deals
The MASH space in 2025 witnessed three major Big Pharma acquisitions.
1. GSK → Boston Pharmaceuticals (May 2025)
In May 2025, GSK acquired Boston Pharmaceuticals' lead asset, efimosfermin alfa (formerly BOS-580), for an upfront payment of $1.2 billion, with up to $800 million in potential milestone payments12.
Key Asset Characteristics:
- Efimosfermin alfa demonstrated significant improvements in liver fibrosis and MASH resolution in Phase 2 trials involving patients with F2/F3 fibrosis34
- GSK plans to develop the drug for a broader range of steatotic liver diseases (SLD), including MASH and alcohol-related liver disease (ALD), targeting commercialization in 202925
2. Roche → 89bio (September 2025)
In September 2025, Roche acquired 89bio for an upfront payment of $2.4 billion, with an additional $1.1 billion in potential milestone payments (total deal value up to $3.5 billion)67.
Key Asset Characteristics:
- Lead candidate pegozafermin is a fibroblast growth factor 21 (FGF21) analog targeting moderate to severe MASH treatment68
- Phase 3 trials ENLIGHTEN-Fibrosis (non-cirrhotic F2-F3 patients) and ENLIGHTEN-Cirrhosis (compensated cirrhotic F4 patients) are ongoing89
- Topline results from ENLIGHTEN-Fibrosis expected in first half of 2027, and ENLIGHTEN-Cirrhosis in first half of 20289
3. Novo Nordisk → Akero Therapeutics (October 2025)
In October 2025, Novo Nordisk acquired Akero Therapeutics for an upfront payment of $4.7 billion, with up to an additional $500 million contingent upon FDA approval for compensated cirrhosis due to MASH1011.
Key Asset Characteristics:
- Lead candidate efruxifermin (EFX) is an FGF21 analog that Novo Nordisk believes has "first- and best-in-class" potential for MASH1012
- Under development in Phase 3 SYNCHRONY program for both pre-cirrhotic MASH (F2-F3) and compensated cirrhosis (F4)1314
- 96-week results from Phase 2b SYMMETRY trial announced in January 2025 showed statistically significant improvement of compensated cirrhosis (F4) due to MASH15
Approved Therapeutics
Madrigal Pharmaceuticals - Rezdiffra (resmetirom)
- FDA approval obtained in March 2024, conditional marketing authorization from European Commission in August 20251617
- Industry's first approved drug for MASH treatment with F2-F3 fibrosis, leading the market16. Non-invasive biomarkers (FIB-4, ELF test, etc.) played a critical role as surrogate endpoints in approval trials (particularly the ELF score, which received FDA De Novo authorization as a prognostic marker)
- Launched in Germany in September 202517
Novo Nordisk - Wegovy (semaglutide)
- In August 2025, FDA approved for treatment of adult MASH patients with moderate to advanced liver fibrosis (without cirrhosis)1819
- In December 2025, Health Canada also granted conditional marketing authorization for non-cirrhotic MASH (F2-F3 fibrosis)20
Companies Seeking Partners
Viking Therapeutics
- Phase 2b VOYAGE trial of lead candidate VK2809 showed favorable 52-week histological data2122
- CEO stated that "a large partner would be very helpful in driving the program through commercialization" and expressed openness to partnership negotiations2324
- Plans to discuss Phase 3 strategy with FDA23
Retreating Companies
Gilead Sciences
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
Industry Map: Visualizing Company Relationships
The following Mermaid diagram visualizes the major acquisitions, approvals, and development status in the MASH space in 2025.
Legend:
- 🔵 Blue: Big Pharma (acquiring companies)
- 🟢 Green: Approved companies
- 🔴 Red: Retreating/discontinued companies
- 🟠 Orange: Companies seeking partners
Analysis: Industry Trend Analysis
1. Big Pharma Acquisition of De-Risked Assets
All three major MASH acquisitions in 2025 (GSK/Boston, Roche/89bio, Novo/Akero) involved "de-risked" assets with positive Phase 2 or later data. This demonstrates Big Pharma's strategy of avoiding early-stage development risks and entering the market after some degree of efficacy has been confirmed.
2. Concentration on FGF21 Analogs
Both pegozafermin (89bio) and efruxifermin (Akero), acquired by Roche and Novo Nordisk respectively, are FGF21 analogs. This concentration indicates that the FGF21 pathway is being valued as a differentiated mechanism for anti-fibrotic and anti-inflammatory effects.
3. Indication Expansion and Combination Strategies
GSK's efimosfermin alfa is pursuing indication expansion beyond MASH to alcohol-related liver disease (ALD). Additionally, the possibility of combination therapy with existing anti-fibrotic drugs is being explored, suggesting that combination strategies will become increasingly important in future development.
Conclusion
The MASH space in 2025 experienced accelerated industry consolidation with multiple Big Pharma mega-acquisitions. GSK, Roche, and Novo Nordisk invested over $8 billion collectively to acquire promising biotech assets and secure market entry.
Going forward, all eyes are on Phase 3 readouts and regulatory decisions for these acquired assets. Whether the FGF21 analogs secured by Roche and Novo Nordisk deliver compelling clinical data in 2027 and beyond will largely determine the future trajectory of MASH therapy.
FAQ
Q: Why did Big Pharma cluster so tightly around FGF21 analogs in 2025? A: FGF21 is one of the few targets that simultaneously drives hepatic lipid metabolism, anti-fibrotic effects, and anti-inflammatory activity. Phase 2 data showed significant F2-F3 fibrosis improvement, and its subcutaneous dosing regimen (weekly to bi-weekly) is patient-friendly and combines cleanly with GLP-1 agonists. The main differentiator between pegozafermin (89bio) and efruxifermin (Akero) is PK profile and dosing frequency.
Q: Will Rezdiffra (resmetirom) and the upcoming FGF21 analogs compete directly? A: Short term yes, long term they likely combine. Rezdiffra (THR-β agonist) is strong on hepatic lipid lowering and MASH resolution; FGF21 analogs differentiate on fibrosis reversal and insulin sensitization. With distinct MoAs, "THR-β + FGF21" and "GLP-1 + FGF21" Phase 2/3 combination trials will dominate the 2027+ landscape. See MASH combination therapy strategy 2026.
Q: What does Gilead's MASH exit signal for the industry? A: Gilead shelved its cilofexor (FXR) + firsocostat (ACC) + semaglutide triple-combo strategy in 2024–2025. The core cause: Rezdiffra's approval raised the baseline SoC, making it dramatically harder to demonstrate add-on benefit for a triple combination. This is a structural headwind for all later-entrant combination programs.
Q: Why is Viking Therapeutics (VK2809) still seeking a partner rather than being acquired? A: VK2809 is a THR-β agonist — same class as Rezdiffra — so Big Pharma views it as a "me-too asset competing against an already-approved drug." Meanwhile Viking also owns VK2735 (GLP-1/GIP dual agonist) and VK0612, creating valuation tension: acquirers have to decide between a full takeout vs. a VK2809-only license. That mismatch is why partner conversations are stalled.
Q: Where do Japanese pharma companies stand in MASH development? A: Otsuka (OPC-163493) and a few Kyowa Kirin exploratory programs remain in early stages, but no purely Japan-originated MASH drug has reached global Phase 3. Takeda has already exited antifibrotic strategy. The practical paths for Japanese players today are (a) out-licensing early-stage assets, or (b) acquiring Japan-market rights to overseas Phase 3 candidates.
Moving forward, the Phase 3 results and regulatory approvals of these acquired assets will be closely watched. Particularly, the clinical performance of the FGF21 analogs acquired by Roche and Novo Nordisk from 2027 onwards will significantly shape the future of MASH treatment.
Related Articles
- Comprehensive Guide to MASLD/MASH Biomarkers — The complete picture of non-invasive biomarkers essential for MASH clinical development, including FIB-4, ELF test, and Pro-C3
- Anti-Fibrotic Drug Pipeline 2026: Cross-Disease Approaches — Latest developments in pan-fibrosis therapeutics spanning IPF, MASH, and CKD
- MASH Therapeutics Comprehensive Analysis: Pipeline by Mechanism — Detailed analysis of major MASH drug candidates by MOA, clinical stage, and competitive landscape
- MASH Combination Therapy Strategies 2026 — Frontier of GLP-1 + FGF21, GLP-1 + THR-β, and other combination approaches
- The Future of MASH: Post-2030 Treatment Paradigm Shifts — Next-generation modalities, gene therapy, and prevention strategies
- ALD vs MASLD Models: Alcoholic vs Metabolic Liver Disease — Selection criteria and pathology differences between ALD and MASLD models
- MASH Model Selection Guide: MoA-Based Decision Matrix — Compare GAN, CDA-HFD, CCl4, STAM and more by drug mechanism of action
References
1.GSK Acquires Boston Pharmaceuticals' MASH Asset - MedCity News
2.GSK to Acquire Boston Pharmaceuticals - Contract Pharma
3.Boston Pharmaceuticals Announces Positive Phase 2 Results - Clinical Trial Vanguard
4.Boston Pharmaceuticals Phase 2 Data - Business Wire
5.GSK MASH Pipeline Expansion - Nasdaq
6.Roche to Acquire 89bio - Fierce Biotech
7.Roche 89bio Acquisition Analysis - BioPharma Dive
8.Roche and 89bio Deal Overview - Pharma Phorum
9.89bio ENLIGHTEN Trials Update - MedCity News
10.Novo Nordisk Acquires Akero - MedCity News
11.Novo Nordisk and Akero Deal - BioPharma Dive
12.Novo Nordisk Akero Strategy - BioSpace
13.Akero SYNCHRONY Program Overview
14.Akero Clinical Development Update
15.Akero Phase 2b SYMMETRY Results - BioPharma Dive
16.Madrigal Rezdiffra Approval - BioSpace
17.Madrigal European Approval - BioSpace
18.Wegovy MASH Approval - Pharmaceutical Technology
19.Novo Nordisk Wegovy MASH - PharmTech
20.Wegovy Canada Approval - Newswire
21.Viking Therapeutics VK2809 Data - BioSpace
22.Viking VOYAGE Study Results
23.Viking Therapeutics Partnership Strategy - Fierce Biotech
24.Viking Therapeutics M&A Speculation - BioPharma Dive